Scarica l'app Stockscreener
3.03
38.36%
0.84
Dopo l'orario di chiusura:
2.96
-0.07
-2.31%
Precedente Chiudi:
$2.19
Aprire:
$2.2
Volume 24 ore:
6.04M
Relative Volume:
21.41
Capitalizzazione di mercato:
$428.47M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+61.17%
1M Prestazione:
+0.00%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$2.10
$3.04
Intervallo di 1 settimana:
$1.70
$3.04
Portata 52W:
$1.70
$26.01
Veraxa Biotech Ag Stock (VRXA) Company Profile
Nome
Veraxa Biotech Ag
Settore
Industria
Telefono
-
Indirizzo
-
Compare VRXA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRXA
Veraxa Biotech Ag
|
3.03 | 309.68M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Veraxa Biotech Ag Borsa (VRXA) Ultime notizie
VERAXA Biotech (VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition - NewMediaWire
Non-controlling/minority interest of Veraxa Biotech AG – BOATS:VRXAW - TradingView
VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Watch Novartis Latest $1.5B ADC Acquisition - The Globe and Mail
VRXA | Veraxa Biotech AG Ordinary Stock Data, Price & News - Quiver Quantitative
VERAXA Biotech Advances BiTAC Pipeline and Partnering Strategy in First Half of 2026 - citybuzz -
VERAXA Biotech Advances BiTAC Pipeline, Seeks Pharma Partnerships to Fund Cancer Therapies - citybuzz -
VERAXA Biotech (NASDAQ: VRXA) Highlights BiTAC Pipeline Progress, Advances Partnering Strategy - TradingView
The Cancer Therapy Strategy VERAXA Is Betting the Company On - Yahoo Finance
VERAXA Biotech targets 2028 IND filing for lead candidate By Investing.com - Investing.com South Africa
VERAXA Biotech advances cancer therapy pipeline focusing on BiTAC technology and seeks partnerships. - Pluang
VERAXA Biotech AG Provides Pipeline and Partnering Update, Advances BiTAC Development Strategy - Quiver Quantitative
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines - The Manila Times
VERAXA says its BiTAC cancer pipeline is drawing partner interest - Stock Titan
VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone - Yahoo Finance
VERAXA Biotech (VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program - NewMediaWire
VERAXA Biotech Begins Cell Line Development for BiTAC Cancer Therapy, Aiming to Improve Tumor Selectivity - citybuzz -
Veraxa Biotech (VRXA) Stock Price, News & Analysis - Stock Titan
Veraxa initiates cell line development for lead cancer therapy By Investing.com - Investing.com Nigeria
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program - The Manila Times
VERAXA advances lead cancer drug toward manufacturing work with ATUM - Stock Titan
Antibody Therapeutics Deals Signal Value Creation for Early-Stage Biotechs Like VERAXA - MEXC
Why VERAXA Biotech (VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals - NewMediaWire
Why VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sect - Benzinga
Price to earnings forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Enterprise value to EBITDA forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Price to book forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Price to sales forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Enterprise value to revenue forward of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
Price to book forward of Veraxa Biotech AG – NASDAQ:VRXA - TradingView
Price to book forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
VRXA|Veraxa Biotech AG Ord Shs|Price:2.320|Chg%:-0.03 - TradingKey
Price to earnings forward of Veraxa Biotech AG – NASDAQ:VRXA - TradingView
Price to earnings forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
Enterprise value to EBIT forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
Enterprise value to EBITDA forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
Veraxa Biotech AG Ord Shs (VRXA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
VRXA: Veraxa Biotech AGInteractive Chart - Zacks Investment Research
Enterprise value to revenue forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
Price to sales forward of Veraxa Biotech AG – FWB:J8L0 - TradingView
Price to sales forward of Veraxa Biotech AG – BOATS:VRXA - TradingView
Enterprise value to EBIT forward of Veraxa Biotech AG – BOATS:VRXA - TradingView
Price to earnings forward of Veraxa Biotech AG – BOATS:VRXA - TradingView
Veraxa Biotech Holding AG (FRA:J8L0) Stock PDF (Updated: 2026/06/26) - GuruFocus
Cash per share of Veraxa Biotech AG – NASDAQ:VRXAW - TradingView
VERAXA Biotech (VRXA) Advances BiTAC-ADC Platform as It Expands Next-Generation Cancer Therapy Pipeline - Yahoo Finance
Price to sales forward of Veraxa Biotech AG – BOATS:VRXAW - TradingView
VERAXA Biotech (NASDAQ: VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline - USA Today
VERAXA Biotech Reports Proof-of-Concept Data for BiTAC-ADC Platform, Seeks Partnerships at BIO 2026 - MEXC
VERAXA Biotech (VRXA) Expands Heidelberg R&D Facilities To Support Drug Development Pipeline - NewMediaWire
VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development - Yahoo Finance
Veraxa Biotech expands Heidelberg lab space By Investing.com - Investing.com Australia
Veraxa Biotech Ag Azioni (VRXA) Dati Finanziari
Non sono disponibili dati finanziari per Veraxa Biotech Ag (VRXA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.18%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):